Excited to co-organize the 2024 ASH Workshop on Therapy Resistance Mechanisms in Blood Malignancies with Panos Panos Ntz and Dan Daniel Starczynowski for the second year! Join us in San Diego on Friday, Dec 6, 2024, 2-5 PM. #ASH2024 ASH

🚨🚨New Preprint!🚨🚨 2nd postdoc paper by Shreeta Chakraborty who is on the job market 🔥👀🔥 We asked whether perturbing TADs that have many developmental regulators can cause very severe phenotypes and the answer was clear: biorxiv.org/content/10.110…

Hallmarks of cancer stemness by Loh (Jia Jian Loh) and Ma (Stephanie Ma) hubs.li/Q02JJ5890 Collection highlight from Cell Stem Cell

Why is #ALL highly curable in #kids but carries a much worse prognosis in #adults?? Check out our new paper Journal of Clinical Oncology describing genomics of age-related differences in ALL drug sensitivity St. Jude Research MD Anderson Cancer Center UChicago Leukemia Program Nitin Jain

Thrilled to share our latest work in Science⁦⁦. We discovered a novel non-mobilizable HSC pool. I really appreciate the huge support from ⁦Uli Steidl⁩ ⁦Britta Will⁩ and all the co-authors. I hope Paul is smiling at all of us from above! science.org/doi/10.1126/sc…

Very happy to share this new work on LAG3 and PD1. Has been a long road to (begin to) sort out how LAG3 functions in CD8 T cell exhaustion. Great work by Shin Ngiow and super collaboration (and 2 other great papers) with Vignali Lab and Dario Vignali cell.com/cell/abstract/…

Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JC…

Very excited for publication of this study using large scale genomics to provide comprehensive insights into the determinants of outcome in standard risk childhood B-ALL with immediate clinical implications. Children’s Oncology Group St. Jude Research ascopubs.org/doi/10.1200/JC…

Nice to see these data out! My takeaways: 1. TP53 still the bad player. 2. MDS-related mutations in the higher benefit group w/ Ven-aza c/w earlier recent studies of RUNX1, ASXL1,etc. 3. Waiting for more data on triplets and/or sequencing on FLT3 outcomes in this context.

A milestone in my career, and I believe, in cancer genomics and our understanding of leukemia. A wonderful collaboration with David Teachey CHOP Research, with Children’s Oncology Group Gabriella Miller Kids First Data Resource Center (led by the stellar Petri Pölönen). St. Jude Research.

Outstanding thread on this concept - it’s so common to show that X target is high or low in cancer and associated with some outcome but tumor/cellular context and mechanistic insights are key for finding meaningful biomarkers and therapeutic dependencies.

new out in Nature nature.com/articles/d4158…

Nature research paper: Stem cells tightly regulate dead cell clearance to maintain tissue fitness go.nature.com/4dzMQn8

Happy to share my thesis work, now online at bioRxiv. We show that LDB1 organizes Enhancer-Promoter interaction networks and can function independently of cohesin! biorxiv.org/content/10.110…

Out today our 3D chromosomal landscape "evolution" paper in pediatric B cell leukemia (B-ALL). We report extensive Hi-C, ATAC- & RNA-seq on matched diagnosis/relapse B-ALL specimens. Work by the fantastic Yohana Ghebrechristos and Sonali Narang at NYU GSOM Pathology and NYU Grossman School of Medicine Nature Communications

YY1-controlled regulatory connectivity and transcription are influenced by the cell cycle | Nature Genetics nature.com/articles/s4158…

Great to finally see this out from Jessica in ⁦⁦blobellab⁩ !! YY1-controlled regulatory connectivity and transcription are influenced by the cell cycle | ⁦Nature Genetics⁩ nature.com/articles/s4158…

Fascinating. Time to update that old central dogma diagram.

📣review alert! How do enhancers activate promoters? Physical contact? Spooky action from a distance? read Peters' review (and thread!) for more... authors.elsevier.com/sd/article/S09…

Excited to share our review in Blood Journal !! Mark Litzow #Dr_Selina_Luger #ALL #leusm #immunotherapy Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. ashpublications.org/blood/article-…